基线视力较好者接受0.19毫克氟轻松玻璃体内植入剂治疗后糖尿病黄斑水肿结局更佳
这项为期3年、4期、开放标签、观察性研究分析了202只眼(159例患者)接受0.19毫克氟轻松玻璃体内植入剂后,基线最佳矫正视力(BCVA)与视力、治疗负担、视网膜厚度变异性(RTV)及眼压相关事件的关系。基线BCVA≥20/40的眼维持了基线视力,而<20/40的眼视力提高约7个字母至61.34个字母(P<0.05);无论基线BCVA如何,治疗负担和RTV均下降。
要点
- 基线BCVA≥20/40的眼在36个月时维持基线视力,<20/40的眼视力提高约7个字母至61.34个字母(P<0.05)。
- 无论基线BCVA如何,接受0.19毫克氟轻松玻璃体内植入剂后治疗负担和视网膜厚度变异性均下降。
- 基线BCVA≥20/40的眼眼压相关事件数值上少于<20/40的眼,包括需要切口性降眼压手术的发生率更低。
核心结论
- 0.19毫克氟轻松玻璃体内植入剂改善视网膜厚度变异性和治疗负担,与基线BCVA无关。
- 基线BCVA≥20/40与长期BCVA维持相关;基线BCVA<20/40的眼BCVA虽显著改善,但从未达到基线BCVA较好者的水平。
- 这些数据表明,在糖尿病黄斑水肿出现显著视力丧失之前进行早期有效干预是维持视力结局的关键。
研究设计与样本
- 为期3年、4期、开放标签、观察性研究,分析基线BCVA与视力、治疗负担、视网膜厚度变异性及眼压相关事件的关系。
- 纳入既往皮质类固醇治疗后眼压无临床显著升高的糖尿病黄斑水肿患者,共202只眼(159例患者)。
- 按基线BCVA≥20/40或<20/40分组分析。
主要发现
- 术后36个月,基线BCVA≥20/40的眼维持基线BCVA,而基线BCVA<20/40的眼视力提高约7个字母至61.34个字母(Snellen等效约20/60;P<0.05)。
- 无论基线BCVA如何,接受0.19毫克氟轻松玻璃体内植入剂后治疗负担和视网膜厚度变异性均下降。
- 基线BCVA≥20/40的眼术后眼压相关事件数值上少于基线BCVA<20/40的眼,包括需要切口性降眼压手术的发生率更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Analysis of a 3-year, Phase 4, open-label, observational study evaluating the association of baseline best-corrected visual acuity (BCVA) with visual, treatment burden, and retinal thickness variability (RTV) outcomes and intraocular pressure (IOP)-related events after the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant. METHODS: Data from patients with diabetic macular edema (DME) who did not have a clinically significant rise in IOP after previous corticosteroid treatment (N = 202 eyes from 159 patients) were segregated by baseline BCVA of ≥20/40 or <20/40 and analyzed for BCVA, number of yearly supplemental DME treatments, RTV, and incidence of IOP-related events. RESULTS: At 36 months post-FAc, eyes with better baseline BCVA (≥20/40) maintained baseline BCVA, whereas vision in eyes with worse baseline BCVA (<20/40) increased by approximately 7 letters to 61.34 letters (Snellen equivalent approximately 20/60; P < 0.05). Treatment burden and RTV decreased post-FAc regardless of baseline BCVA. Eyes with better baseline BCVA (≥20/40) had numerically fewer IOP-related events post-FAc versus eyes with worse baseline BCVA (<20/40), including a lower incidence of incisional IOP-lowering surgery. CONCLUSION: The 0.19-mg FAc implant improved RTV and treatment burden regardless of baseline BCVA. Better baseline BCVA (≥20/40) was associated with long-term BCVA maintenance. Although eyes with worse baseline BCVA (<20/40) experienced significantly improved BCVA, it never rose to the level of those with better baseline BCVA. These data indicate that early, effective intervention in DME, before significant vision loss occurs, is key to maintaining visual outcomes.
引用
- Gonzalez VH, Luo C, Almeida DRP, et al. BETTER BASELINE VISION LEADS TO BETTER OUTCOMES AFTER THE 0.19-mg FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN DIABETIC MACULAR EDEMA. Retina. 2023. PMID: 37130434. doi:10.1097/IAE.0000000000003827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。